1 / 10

It’s right. Next to the Heart.

It’s right. Next to the Heart. Maynard (Mike) Ramsey, MD, PhD CEO/CSO. CardioCommand Mission.

feoras
Download Presentation

It’s right. Next to the Heart.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. It’s right. Next to the Heart.

  2. Maynard (Mike) Ramsey, MD, PhD CEO/CSO CardioCommand Mission “As the inventor of DinamapTM20 years ago, I believed technology could make a real clinical contribution in the noninvasive monitoring of arterial blood pressure. Today, technology must also enable more efficient healthcare delivery.” CardioCommand has pioneered a new class of noninvasive technology that can diagnose, monitor and treat the heart. More efficient healthcare.

  3. Meeting a growing need CardioCommand provides clinicians with safer and faster treatment and diagnostic options for achieving optimum heart rate. Its technology combines safe heart rate control with breakthrough monitoring parameters to help minimize patient risk from known or unrecognized heart disease in both acute care and diagnostic settings. More at-risk patients.

  4. CardioCommand products exploit the close anatomical proximity between the esophagus and the left atrium of the heart. Since CardioCommand applications are administered across the anterior esophageal wall, they are referred to as transesophageal, and hence are noninvasive in their approach to pacing (TAP) and monitoring. CardioCommand transesophageal catheter Atrium Ventricle Pacing and recording electrodes The Esophageal Window to the Heart Noninvasive, safe and efficient.

  5. TAP-all G3 patients responded Study- 64 patients 70% became bradycardic Study notes: 66% of G1 & 53% of G2 required 2nd drug dose 1 G2 required 3rd drug dose & 1 G2 had no drug response after 4 drug doses & was treated successfully with TAP Treatment groups: G1 15 pts atropine, G2 15 pts glycopyrrolate, G3 15 pts TAPSCOPE, 19 pts control & untreated (Smith, Ian, et.al. Anesth Analg 1994;78:245-52) TAPSCOPETM . . . for perioperative hemodynamic management Predictable heart rate control.

  6. Faster Study Times More Efficacious Safer Greater Staff Efficiencies VIDEO on Menu TAPSTRESSTM . . . for non-exercise stress echocardiography • 100 patients comparing TAPSTRESSTM and Mayo standard dobutamine stress echo protocol • RESULTS: TAPSTRESSTMdobutamine -minutes: test+recovery 9.6 29.0 -achieved target HR 98 % 89 % -symptoms/dysrhythmias few more -wall motion concordance good good -labor intensity of test less greater *Lee, Pellikka, et al, Nonexercise Stress Transthoracic Echocardiography: Transesophageal Atrial Pacing versus Dobutamine Stress. JACC, 1999; 33:506-11 Reimbursable, out-of-hospital testing.

  7. Transient atrial fibrillation before conversion to sinus rhythm Cardioversion of atrial flutter using transesophageal burst pacing Skin electrode ECG Esophageal ECG provides superior atrial arrhythmia information TAPCATHTM . . . for electrophysiology & cardioversion No anesthesia, no intracardiac catheters.

  8. Compelling and growing needs • Esophageal V lead connection Perioperative MI 150,000 cases per year & 50,000 associated deaths Chest Pain & Acute MI 8,000,000 chest pain ED visits per year & 500,000 deaths Atrial Fibrillation 3,000,000 patients & leading cause of stroke And the promise of a new approach.

  9. About CardioCommand • CardioCommand has 9 products with FDA PMA approval for US distribution and 29 issued US and International patents in the areas of transesophaeal pacing and cardioversion. • Over 200 scientific articles have investigated & validated transesophageal technology and applications • CardioCommand, Inc. operated as ARZCO Medical Systems, Inc. from 1994 until 1998 • CardioCommand’s corporate headquarters are located in Tampa, Florida, under the direction of Maynard (Mike) Ramsey, MD, PhD World’s leader in transesophageal technology.

  10. It’s right. Next to the Heart.

More Related